You just read:

Santaris Pharma A/S Advances a Second Drug From Its Cardiometabolic Program, SPC4955, Inhibiting apoB, into Phase 1 Clinical Trials for the Treatment of High Cholesterol

News provided by

Santaris Pharma A/S

11 May, 2011, 12:15 BST